Product Description
In vivo CRISPR/Cas9-based Factor 9 gene insertion therapy. (Sourced from: https://investor.regeneron.com/news-releases/news-release-details/regeneron-highlight-scientific-advancements-across-diversified)
Mechanisms of Action: Gene Therapy
Novel Mechanism: No
Modality: Gene Therapy
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Regeneron
Company Location: TARRYTOWN NY 10591
Company CEO: Leonard S. Schleifer
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for LNP-1265](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic: Germany
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Hemophilia A|Hemophilia B
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
BEYOND-9 | P2 |
Not yet recruiting |
Hemophilia B|Hemophilia A |
2032-07-03 |
24% |
BEYOND-9 | P2 |
Not yet recruiting |
Hemophilia B|Hemophilia A |
2032-07-03 |
24% |
R131L1265-HEMB-2318 | P2 |
Not yet recruiting |
Hemophilia B |
2029-07-27 |